Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11040640 | 0.98 | LMNA (0.47) | LMNAPKMNPSR1CCR8KCNH2 | |
| SCHEMBL435089 | 0.78 | LMNA (0.49) | LMNAPKMNPSR1ALDH1A1KDM4E | |
| SCHEMBL29015919 | 0.78 | LMNA (0.52) | LMNAALDH1A1MAPTPOLBNPC1 | |
| SCHEMBL30350713 | 0.77 | LMNA (0.48) | LMNAPKMNPSR1ALDH1A1KDM4E | |
| SCHEMBL10737745 | 0.77 | PKM (0.50) | LMNAPKMNPSR1ALDH1A1KDM4E | |
| SCHEMBL29963948 | 0.77 | LMNA (0.51) | LMNAPKMNPSR1ALDH1A1KDM4E | |
| SCHEMBL16127631 | 0.77 | LMNA (0.48) | LMNAPKMNPSR1ALDH1A1KDM4E | |
| SCHEMBL10610789 | 0.77 | LMNA (0.48) | LMNAPKMNPSR1ALDH1A1KDM4E | |
| SCHEMBL15485106 | 0.77 | LMNA (0.51) | LMNAPKMNPSR1ALDH1A1KDM4E | |
| SCHEMBL18536181 | 0.77 | ALDH1A1 (0.49) | LMNAPKMNPSR1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192220-A1 | TREATMENT FOR SOLID TUMORS | ORE PHARMACEUTICALS INC. (US) | 2009-07-30 | — | — | US | claimed |
| WO-2009067397-A2 | TREATMENT FOR SOLID TUMORS | ORE PHARMACEUTICALS INC. (US) | 2009-05-28 | — | — | WO | claimed |
| CN-116265457-B | N-oxa condensed ring amide compound and preparation method and application thereof | 湖南化工研究院有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2023144736-A1 | COMPOSITIONS FOR PREVENTING OR TREATING PULMONARY ARTERIAL HYPERTENSION | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023144737-A1 | COMPOSITIONS FOR PREVENTING OR TREATING HEART FAILURE (HF) | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-03 | — | — | WO | disclosed |
| CN-116265457-A | N-oxa condensed ring amide compound and preparation method and application thereof | 湖南化工研究院有限公司 | 2023-06-20 | — | — | CN | disclosed |
| WO-2023031775-A1 | COMPOSITIONS FOR PREVENTING OR TREATING CHARCOT-MARIE-TOOTH DISEASE (CMT) | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-03-09 | — | — | WO | disclosed |
| WO-2021239058-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-12-02 | — | — | WO | disclosed |
| US-9846160-B2 | Ganglioside GD2 as a marker and target on cancer stem cells | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2017-12-19 | — | — | US | disclosed |
| US-9846160-B2 | Ganglioside GD2 as a marker and target on cancer stem cells | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2017-12-19 | — | — | US | disclosed |
| US-9846160-B2 | Ganglioside GD2 as a marker and target on cancer stem cells | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2017-12-19 | — | — | US | disclosed |
| US-4748186-A | NEMATOCIDES, ANTHELMINTICS | FMC CORPORATION (US) | 1988-05-31 | — | — | US | disclosed |
| US-4743291-A | Herbicidal aryl triazolinones | FMC CORPORATION (US) | 1988-05-10 | — | — | US | disclosed |
| WO-1988000183-A1 | S-TRIFLUOROBUTENYL DERIVATIVES AND PESTICIDAL USES | FMC CORPORATION (US) | 1988-01-14 | — | — | WO | disclosed |
| US-4695310-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-09-22 | — | — | US | disclosed |
| EP-0079683-B1 | HERBICIDAL SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-05-06 | — | — | EP | disclosed |
| US-4647677-A | Process for preparing 2,3-dihydro-7-aminobenzofurans | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1987-03-03 | — | — | US | disclosed |
| US-4589909-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-05-20 | — | — | US | disclosed |
| US-4514211-A | HERBICIDES, PLANT GROWTH REGULATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-04-30 | — | — | US | disclosed |
| EP-0079683-A2 | Herbicidal sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192220-A1 | TREATMENT FOR SOLID TUMORS | ACAT2, ACAT1, APRT | LMNA 3368/4885PKM 512/4885NPSR1 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.